{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-012080","form_type":"8-K","ticker":null,"cik":"0000849636","company_name":"RespireRx Pharmaceuticals Inc.","filed_at":"2023-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.428689+00:00","generated_at":"2026-06-17T02:52:42.867226+00:00","sec_items":["1.01","3.02","5.02","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"RespireRx issues Series J preferred to settle $570K of officer/vendor liabilities","bullets":["Exchanged $570K of accrued compensation/debt for 5,700 shares of Series J 8% voting preferred stock.","Margolis (CFO) and Lippa (Interim CEO) each received 2,100 shares; vendor Radin received 1,500 shares.","Series J shares have $100 stated value, 8% annual dividend payable in stock, and 100x voting rights.","Redemption triggers include upfront payments, milestones, or royalties ≥$20M; liquidation preference before common.","Shares transferred immediately to trusts/affiliates; unregistered offering under Section 4(a)(2)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-012080","json":"https://secwatch.observer/filing/0001493152-23-012080.json","markdown":"https://secwatch.observer/filing/0001493152-23-012080.md","text":"https://secwatch.observer/filing/0001493152-23-012080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/849636/000149315223012080/0001493152-23-012080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/849636/000149315223012080/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T02:52:42.867226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"973e565b2d71e69053b905a8100aa43c5c8d4e6b","claim":"RespireRx Pharmaceuticals Inc.: Amendment to certificate of incorporation to establish Series J 8% Voting, Participating, Redeemable Preferred Stock (effective 2023-04-12).","evidence_excerpt":"On April 11, 2023 , the Company’s Board of Directors authorized an amendment to the Company’s certificate of incorporation to establish a Series J 8% Voting, Participating, Redeemable Preferred Stock (Series J Certificate of Designation”). On April 12, 2023, the Company filed the Series J Certificate of Designation with the Secretary of State of the state of Delaware.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/849636/000149315223012080/0001493152-23-012080-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-04-12"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}